199 related articles for article (PubMed ID: 33166926)
1. Redirecting cytotoxic T cells with chemically programmed antibodies.
Qi J; Rader C
Bioorg Med Chem; 2020 Dec; 28(24):115834. PubMed ID: 33166926
[TBL] [Abstract][Full Text] [Related]
2. Chemically Programmed Bispecific Antibodies in Diabody Format.
Walseng E; Nelson CG; Qi J; Nanna AR; Roush WR; Goswami RK; Sinha SC; Burke TR; Rader C
J Biol Chem; 2016 Sep; 291(37):19661-73. PubMed ID: 27445334
[TBL] [Abstract][Full Text] [Related]
3. Chemically programmed bispecific antibodies that recruit and activate T cells.
Cui H; Thomas JD; Burke TR; Rader C
J Biol Chem; 2012 Aug; 287(34):28206-14. PubMed ID: 22761439
[TBL] [Abstract][Full Text] [Related]
4. Bispecific antibodies in cancer immunotherapy.
Rader C
Curr Opin Biotechnol; 2020 Oct; 65():9-16. PubMed ID: 31841859
[TBL] [Abstract][Full Text] [Related]
5. Targeting T cells with bispecific antibodies for cancer therapy.
Lum LG; Thakur A
BioDrugs; 2011 Dec; 25(6):365-79. PubMed ID: 22050339
[TBL] [Abstract][Full Text] [Related]
6. Optimization of T Cell Redirecting Strategies: Obtaining Inspirations From Natural Process of T Cell Activation.
Gao Y; Wang Y; Luo F; Chu Y
Front Immunol; 2021; 12():664329. PubMed ID: 33981310
[TBL] [Abstract][Full Text] [Related]
7. Conventional and Chemically Programmed Asymmetric Bispecific Antibodies Targeting Folate Receptor 1.
Qi J; Hymel D; Nelson CG; Burke TR; Rader C
Front Immunol; 2019; 10():1994. PubMed ID: 31497024
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy.
Rashidijahanabad Z; Huang X
Semin Immunol; 2020 Feb; 47():101390. PubMed ID: 31982247
[TBL] [Abstract][Full Text] [Related]
9. Chemically Programmable and Switchable CAR-T Therapy.
Qi J; Tsuji K; Hymel D; Burke TR; Hudecek M; Rader C; Peng H
Angew Chem Int Ed Engl; 2020 Jul; 59(29):12178-12185. PubMed ID: 32329959
[TBL] [Abstract][Full Text] [Related]
10. Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.
Qi J; Li X; Peng H; Cook EM; Dadashian EL; Wiestner A; Park H; Rader C
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):E5467-E5476. PubMed ID: 29844189
[TBL] [Abstract][Full Text] [Related]
11. Engineering Immune Cells for
Blanco B; Ramírez-Fernández Á; Alvarez-Vallina L
Front Immunol; 2020; 11():1792. PubMed ID: 32903593
[TBL] [Abstract][Full Text] [Related]
12. Switchable CAR-T Cells Outperformed Traditional Antibody-Redirected Therapeutics Targeting Breast Cancers.
Cao YJ; Wang X; Wang Z; Zhao L; Li S; Zhang Z; Wei X; Yun H; Choi SH; Liu Z; Zhao L; Kazane SA
ACS Synth Biol; 2021 May; 10(5):1176-1183. PubMed ID: 33856201
[TBL] [Abstract][Full Text] [Related]
13. Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors.
Satta A; Mezzanzanica D; Turatti F; Canevari S; Figini M
Future Oncol; 2013 Apr; 9(4):527-39. PubMed ID: 23560375
[TBL] [Abstract][Full Text] [Related]
14. Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells.
Thakur A; Scholler J; Kubicka E; Bliemeister ET; Schalk DL; June CH; Lum LG
Front Immunol; 2021; 12():690437. PubMed ID: 34290709
[TBL] [Abstract][Full Text] [Related]
15. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas.
Lum HE; Miller M; Davol PA; Grabert RC; Davis JB; Lum LG
Anticancer Res; 2005; 25(1A):43-52. PubMed ID: 15816517
[TBL] [Abstract][Full Text] [Related]
16. T Cell-Redirecting Strategies to 'STAb' Tumors: Beyond CARs and Bispecific Antibodies.
Blanco B; Compte M; Lykkemark S; Sanz L; Alvarez-Vallina L
Trends Immunol; 2019 Mar; 40(3):243-257. PubMed ID: 30827461
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.
Suzuki M; Curran KJ; Cheung NK
Pediatr Blood Cancer; 2015 Aug; 62(8):1326-36. PubMed ID: 25832831
[TBL] [Abstract][Full Text] [Related]
18. Human melanoma therapy in the SCID mouse: in vivo targeting and reactivation of melanoma-specific cytotoxic T cells by bi-specific antibody fragments.
Cochlovius B; Perschl A; Adema GJ; Zöller M
Int J Cancer; 1999 May; 81(3):486-93. PubMed ID: 10209966
[TBL] [Abstract][Full Text] [Related]
19. Activated T cells armed with bispecific antibodies kill tumor targets.
Bhutani D; Lum LG
Curr Opin Hematol; 2015 Nov; 22(6):476-83. PubMed ID: 26457960
[TBL] [Abstract][Full Text] [Related]
20. [Bispecific antibodies: An old story with a bright future… with CAR-T cells!].
Riffard C; Teillaud JL
Bull Cancer; 2021 Oct; 108(10S):S168-S180. PubMed ID: 34920800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
